Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Maruho, Galderma Team Up to Develop, Market Skin Treatments in Japan
January 19, 2016
- Toa Eiyo to Take Over Astellas’s Marketing Authorization for Cibenol
January 19, 2016
- GSK to Resume Shipment of Hep B Drug Tenozet
January 18, 2016
- Novartis Partners with Meiji Seika Pharma to Promote COPD Drugs
January 18, 2016
- Ethical Drug Sales Jump 15.2% in November: Crecon Report
January 18, 2016
- MSD Renews Call for Reinstating Govt’s HPV Vaccine Promotion after WHO Statement
January 15, 2016
- Ono Files Etelcalcetide for Secondary Hyperparathyroidism in Japan
January 15, 2016
- Ribomic Inks New Agreement with Otsuka on Midkine Aptamer; Otsuka to Decide on In-Licensing by Year-End
January 15, 2016
- INDEE Medical Obtains Exclusive Distribution Rights in Japan for Autologous Epidermis Transplant Kit from Australian Company
January 15, 2016
- Weber Says Takeda Made “Big Decision” to Pull Plug on Metabolic R&D
January 14, 2016
- Iwaki Top Brass to Return Remunerations over Embezzlement Issue
January 14, 2016
- Mundipharma Looks to Double Japan Sales of OTC Isodine Products in 5 Years
January 14, 2016
- Lenvima Filed for RCC Indication in EU: Eisai
January 13, 2016
- Enbrel Biosimilar Meets Equivalence Criteria in Global PIII: Daiichi Sankyo
January 13, 2016
- Takeda Allies with Canada’s enGene to Develop GI Disease Therapies
January 13, 2016
- Takeda, US Biotech NsGene Team Up on Cell Encapsulation Therapies for Parkinson’s
January 12, 2016
- Otsuka Files Leukemia Drug Ponatinib in Japan
January 12, 2016
- Lilly Japan, Torii Link Up to Copromote Psoriasis Drug Ixekizumab
January 12, 2016
- Astellas, Boehringer Extend Copromotion Pact for Micardis
January 8, 2016
- Sanofi Launches Japan PIII on Vaccine for C. Diff Infection
January 8, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…